Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Langer

Showing results (91-100 of 160) with videos related to

Pageof 16
Sort By:
Frontiers in Neuroscience|August 4, 2017
Reproducibility of Quantitative Brain Imaging Using a PET-Only and a Combined PET/MR SystemMartin L Lassen, Otto Muzik, Thomas Beyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2009
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PETClaudia C Wagner, Martin Bauer, Rudolf Karch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2008
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PETJens P Bankstahl, Claudia Kuntner, Aiman Abrahim, et al.
Nuclear Medicine and Biology|September 18, 2012
Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113Severin Mairinger, Thomas Wanek, Claudia Kuntner, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 11, 2023
Influence of P-glycoprotein on pulmonary disposition of the model substrate [<sup>11</sup>C]metoclopramide assessed by PET imaging in ratsSeverin Mairinger, Irene Hernández-Lozano, Thomas Filip, et al.
Seizure|May 22, 2024
Tolerability of tariquidar - A third generation P-gp inhibitor as add-on medication to antiseizure medications in drug-resistant epilepsyMaria Ilyas-Feldmann, Oliver Langer, Martin Bauer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 7, 2022
Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in ratsSeverin Mairinger, Irene Hernández-Lozano, Thomas Filip, et al.
Nuclear Medicine and Biology|November 13, 2016
On the applicability of [<sup>18</sup>F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapyCatrin Grunewald, Michael Sauberer, Thomas Filip, et al.
EJNMMI Radiopharmacy and Chemistry|December 5, 2025
Evaluating methodological constraints in PET imaging of neuropeptide Y2 receptors with N-[<sup>11</sup>C]-methyl-(R)-JNJ-31020028 in brains of C57BL/6J miceKarsten Bamminger, Eduardo Felipe Alves Fernandes, Lena Zachhuber, et al.
Nuclear Medicine and Biology|January 27, 2004
A novel electrophilic synthesis and evaluation of medium specific radioactivity (1R,2S)-4-[18F]fluorometaraminol, a tracer for the assessment of cardiac sympathetic nerve integrity with PETOlli Eskola, Tove Grönroos, Jörgen Bergman, et al.
Pageof 16

Showing results (91-100 of 160) with videos related to

Sort By:
Pageof 16
Frontiers in Neuroscience|August 4, 2017
Reproducibility of Quantitative Brain Imaging Using a PET-Only and a Combined PET/MR SystemMartin L Lassen, Otto Muzik, Thomas Beyer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2009
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PETClaudia C Wagner, Martin Bauer, Rudolf Karch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2008
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PETJens P Bankstahl, Claudia Kuntner, Aiman Abrahim, et al.
Nuclear Medicine and Biology|September 18, 2012
Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113Severin Mairinger, Thomas Wanek, Claudia Kuntner, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 11, 2023
Influence of P-glycoprotein on pulmonary disposition of the model substrate [<sup>11</sup>C]metoclopramide assessed by PET imaging in ratsSeverin Mairinger, Irene Hernández-Lozano, Thomas Filip, et al.
Seizure|May 22, 2024
Tolerability of tariquidar - A third generation P-gp inhibitor as add-on medication to antiseizure medications in drug-resistant epilepsyMaria Ilyas-Feldmann, Oliver Langer, Martin Bauer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 7, 2022
Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in ratsSeverin Mairinger, Irene Hernández-Lozano, Thomas Filip, et al.
Nuclear Medicine and Biology|November 13, 2016
On the applicability of [<sup>18</sup>F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapyCatrin Grunewald, Michael Sauberer, Thomas Filip, et al.
EJNMMI Radiopharmacy and Chemistry|December 5, 2025
Evaluating methodological constraints in PET imaging of neuropeptide Y2 receptors with N-[<sup>11</sup>C]-methyl-(R)-JNJ-31020028 in brains of C57BL/6J miceKarsten Bamminger, Eduardo Felipe Alves Fernandes, Lena Zachhuber, et al.
Nuclear Medicine and Biology|January 27, 2004
A novel electrophilic synthesis and evaluation of medium specific radioactivity (1R,2S)-4-[18F]fluorometaraminol, a tracer for the assessment of cardiac sympathetic nerve integrity with PETOlli Eskola, Tove Grönroos, Jörgen Bergman, et al.
Pageof 16